Efficiently navigated contractual complexities, fostering transparent communication with franchising entities both domestically and internationally.Orchestrated the end-to-end hiring process, tailoring recruitment efforts to meet the specific qualifications required for each role.Ensured adherence to brand standards across operational frameworks, maintaining compliance with stringent international directives.Spearheaded the integration of quality benchmarks within the culinary and beverage sectors, elevating industry standards and product excellence.Pioneered cross-functional initiatives to optimize operational efficiency, enhance customer satisfaction, drive sustained growth, and foster industry recognition.

Orchestrated the VAL-IO Program within the ME access team, using innovative tools to convey our value proposition to stakeholders during and beyond the COVID-19 pandemic. This initiative enhanced interactions with payers and pharmacists, improving patient access to our products over approximately 18 months.Secured significant milestones by enlisting Opdivo in prominent Saudi Arabian sectors, including the National Guard Hospital, Medical Cities, and King Faisal Specialist Hospital, improving patient care and strengthening the Saudi team's position.Cultivated a strategic alliance with SOPA (Saudi Oncology Pharmacy Assembly), the leading body for oncology pharmacists in Saudi Arabia. This collaboration provided access to Key Decision Makers (KDMs) in oncology, influencing strategic directives within the Saudi health system.Led the Resource Planning Management (RPM) initiative for the entire Middle East access team, ensuring alignment with teammates and cross-functional units, and facilitating monthly monitoring and allocation of investments to optimize operational efficiency.Mentored the sales team during the 2020 KAM mentorship program, providing field guidance and training on KAM roles, monitoring progress, and assigning account-specific tasks to improve engagement with KDMs and payers.Played a crucial role in executing the MNP (Medical Need Program) in Saudi Arabia, expediting patient access to our valuable regimen in 1L RCC from September 30, 2019, to March 31, 2020. This initiative highlighted our commitment to enhancing patient outcomes and solidified our market position.

Orchestrated the recruitment of eligible patients for Nivolumab across premier institutions such as KAMC and KFSH-J, MOH sector hospitals including Aseer Central Hospital and Prince Mohamed Bin Nasser Hospital, and leading private sector facilities like Soliman Fakeh Hospital and Saudi German Hospital.Strategically segmented and targeted key accounts and healthcare professionals to optimize Nivolumab's positioning in the competitive immuno-oncology (IO) market, utilizing data-driven insights and market analysis.Delivered exemplary patient service with a focus on speed and innovation, continuously challenging conventional practices to elevate the standard of care.Achieved distinction as the top performer in the oncology team for 2017, demonstrating exceptional sales insight and leadership.Spearheaded Nivolumab's successful implementation and integration across diverse healthcare sectors, significantly improving patient outcomes and driving adoption through comprehensive stakeholder engagement.

Pioneered and executed a transformative strategy to challenge existing norms within prominent institutions such as the National Guard Health Affairs (NGHA) and King Abdulaziz Medical City (KAMC), driving significant operational changes.Conducted comprehensive analyses of each account's circumstances, enabling precise segmentation and targeted engagement with key thought leaders (KTLs) within these hospitals, optimizing outreach and impact.Articulated and emphasized the unique value propositions of our hematology products, ensuring tailored communication and strategic alignment with identified KTLs to enhance product adoption and utilization.Successfully increased the number of chronic myeloid leukemia (CML) patients served, facilitated a substantial rise in Dasatinib consumption within targeted institutes, and significantly surpassed the projected budget by 41%.Earned the accolade of Best Achiever in 2015 within the Hematology-Oncology team, reflecting exceptional performance and contribution to the field.

Strategic Market Penetration:Successfully developed and executed market entry strategies for cardiovascular products, resulting in a 25% increase in market share within the first year.Leveraged data analytics to identify and target high-potential accounts, optimizing resource allocation and maximizing outreach efficiency.Enhanced Stakeholder Engagement:Built and maintained strong relationships with key opinion leaders (KOLs), healthcare providers, and payers, leading to a 40% increase in product adoption.Organized and led educational workshops and seminars, significantly improving stakeholders' understanding and support of cardiovascular product benefits.Sales Performance and Revenue Growth:Consistently exceeded sales targets, achieving an average of 30% above the annual sales quota over a three-year period.Implemented innovative sales strategies that drove a 50% increase in revenue for the cardiovascular product line.

Strategic Market Development:Spearheaded market development initiatives for CNS products, resulting in a 30% increase in market penetration within the first year.Utilized advanced market analysis techniques to identify and target high-potential segments, optimizing promotional efforts and resource allocation.Key Stakeholder Engagement:Established and nurtured strong relationships with key opinion leaders (KOLs), neurologists, and psychiatrists, leading to a 35% increase in product endorsements and utilization.Coordinated and led educational forums and workshops, significantly enhancing healthcare providers' knowledge and support of CNS therapies.Sales Performance and Revenue Growth:Consistently exceeded sales targets, achieving an average of 28% above the annual sales quota over a three-year period.Implemented innovative sales strategies that drove a 45% increase in revenue for the CNS product portfolio.

Effective Territory Management:Demonstrated proficiency in managing a diverse territory, achieving consistent growth in market share and exceeding sales targets by an average of 20% annually.Implemented targeted promotional strategies and customer engagement initiatives that resulted in expanded market reach and increased product adoption.Expert Stakeholder Engagement:Established and maintained strong relationships with healthcare professionals, including physicians, pharmacists, and key opinion leaders, enhancing brand advocacy and product endorsement.Organized and conducted educational programs and seminars, effectively communicating the therapeutic benefits and clinical data of BMS products.Sales Performance and Revenue Growth:Consistently ranked as a top performer within the sales team, recognized for exceeding sales goals and contributing to the company's revenue growth.Introduced innovative sales tactics and negotiation strategies that led to a significant increase in sales revenue for assigned product lines.